{"filing":{"accession_number":"0001193125-26-335056","cik":"0000873303","ticker":"SRPT","company_name":"Sarepta Therapeutics, Inc.","form":"8-K","filing_date":"2026-08-05","report_date":"2026-08-05","primary_document":"srpt-20260805.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/873303/000119312526335056/srpt-20260805.htm"},"events":[{"id":24723,"run_id":22418,"accession_number":"0001193125-26-335056","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"summary":"Sarepta issued a press release on August 5, 2026 announcing its financial results for the quarter ended June 30, 2026, disclosing Q2 2026 net product revenues of $328.7 million, GAAP operating income of $13.3 million, and non-GAAP operating income of $86.5 million. The filing explicitly states this is furnished as Exhibit 99.1 under Item 2.02 (Results of Operations and Financial Condition), which is the standard Item for earnings releases. The disclosure includes detailed financial metrics, revenue breakdowns, and forward guidance narrowing FY 2026 total net product revenue guidance to $1.2-$1.3 billion.","company_name":"Sarepta Therapeutics, Inc.","ticker":"SRPT","filing_date":"2026-08-05","form":"8-K","submitted_at":null,"items":[{"id":25378,"accession_number":"0001193125-26-335056","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"Sarepta issued a press release on August 5, 2026 announcing its financial results for the quarter ended June 30, 2026, disclosing Q2 2026 net product revenues of $328.7 million, GAAP operating income of $13.3 million, and non-GAAP operating income of $86.5 million. The filing explicitly states this is furnished as Exhibit 99.1 under Item 2.02 (Results of Operations and Financial Condition), which is the standard Item for earnings releases. The disclosure includes detailed financial metrics, revenue breakdowns, and forward guidance narrowing FY 2026 total net product revenue guidance to $1.2-$1.3 billion.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-07T02:16:13.533658+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":25378,"accession_number":"0001193125-26-335056","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"Sarepta issued a press release on August 5, 2026 announcing its financial results for the quarter ended June 30, 2026, disclosing Q2 2026 net product revenues of $328.7 million, GAAP operating income of $13.3 million, and non-GAAP operating income of $86.5 million. The filing explicitly states this is furnished as Exhibit 99.1 under Item 2.02 (Results of Operations and Financial Condition), which is the standard Item for earnings releases. The disclosure includes detailed financial metrics, revenue breakdowns, and forward guidance narrowing FY 2026 total net product revenue guidance to $1.2-$1.3 billion.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-07T02:16:13.533658+00:00","company_name":"Sarepta Therapeutics, Inc.","ticker":"SRPT","filing_date":"2026-08-05"}]}